Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein

NCT ID: NCT02515526

Last Updated: 2019-09-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2015-08-27

Brief Summary

Protocol title: Effect of acute alcohol consumption on the activity of major cytochrome P450 enzymes, NAT2 and P-glycoprotein.

Objectives: The study is mainly conducted to evaluate the effect of acute alcohol consumption on the activity of the most important drug metabolising cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, intestinal CYP3A4, hepatic CYP3A4, NAT2 and on the activity of the drug transporter p-glycoprotein (intestinal and renal).

The study should also provide basis for a planned clinical study on interactions caused by chronic alcohol intake.

Design: Single center, open-label, two-way, cross-over study with randomly allocated sequences Test-Reference or Reference-Test.

The study is not a clinical drug study according to the German Drug Act.

Clinical phase: Not applicable

Volunteers: 16 healthy male and female subjects are planned for completion in accordance with the protocol, i.e. with evaluable/analysable data for all periods and treatments.

Clinical centre: Department of Pharmacology, Clinical Pharmacology Unit (KPH), University of Cologne, Gleueler Str. 24, 50931Köln, Germany

Conditions

AOD Effects and Consequences

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Reference

A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam

Group Type: ACTIVE_COMPARATOR

caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses

Intervention Type: DRUG

Reference period

Test

A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.

Group Type: EXPERIMENTAL

ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses

Intervention Type: DRUG

Test period

Interventions

caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses

Reference period

Intervention Type: DRUG

ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses

Test period

Intervention Type: DRUG

Other Intervention Names

Percoffedrinol, Tolbutamide PCH, Omepazol Ratiopharm, Hustenstiller Ratiopharm, Digacin and Midazolam-ratiopharm; Percoffedrinol, Tolbutamide PCH, Omepazol Ratiopharm, Hustenstiller Ratiopharm, Digacin, Midazolam-ratiopharm and Wodka Gorbatschow 50%

Eligibility Criteria

Inclusion Criteria

• Caucasian
• Age: 18-55 years
• Normal body weight: (body mass index 18.5-30 kg/m2)
• Considered to be healthy on the basis of extensive pre-study screening
• Willing and capable to confirm written consent prior to enrolment after ample information has been provided.
• Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant ("clinically healthy"). The inclusion criterion "clinically healthy" will be determined both by physical examination and clinical-chemical tests which will be done prior to the clinical part of the study

Exclusion Criteria

• subjects with any relevant clinical abnormality (as based on extensive medical history, physical examination, vital signs and 12-lead ECG)
• subjects with electrolyte disturbances
• subjects with any cardiac arrhythmia
• subjects with a history or evidence of hypertrophic obstructive cardiomyopathy
• subjects with a history or evidence of stenosis of the gastrointestinal tract
• subjects a history or evidence of ulcerative colitis
• subjects a history or evidence of toxic mega colon
• subjects with a history or evidence of myasthenia gravis
• subjects with evidence of chronic infections
• subjects with a history or evidence of bronchial asthma, COPD, pneumonia or other relevant respiratory diseases
• subjects with acute infections within the last two weeks
• subjects with a history of any allergic disease with clinical signs including hay fever and drug allergies
• subjects with suspicion of hypersensitivity to the investigational medications and/or subjects with a history of severe skin reactions
• subjects with any clinically relevant laboratory abnormality (incl. positive results for hepatitis and HIV serology)
• subjects receiving any medication within 1 week prior to study start or during the study (exceptions possible upon decision of Principal Investigator, e.g. paracetamol single dose for acute pain or topical acyclovir for herpes labialis)
• subjects who have taken a drug with a long half-life (> 24 hours) within four weeks before the first trial day
• subjects who received chronic drug treatment (> 3 days) within eight weeks before the first trial day
• subjects who participated in a trial with novel investigational medications within the last 8 weeks before the start of the present study
• subjects who participated in a trial with a registered compound within the last 4 weeks before the start of the present study
• subjects who donated blood or plasma within the last 4 weeks before the start of the present study
• actual smokers defined as subjects who smoked any cigarette during the last three months
• subjects who are known or suspected to be (social) drug dependent, incl. those drinking more than 50 g alcohol per day, those subjects must reduce their consumption to 30 g.
• subjects with a history of alcohol or recreational drug addiction
• subjects with positive drug screening tests
• subjects with a history of any severe disease that might interfere with the study objectives
• subjects who are not willing or able to abstain from alcohol, other than given as a study medication in the Reference period, methylxanthine-containing beverages and foods, caffeine containing products, papaver containing products and grapefruit flesh / juice starting from 72 hours before admission to the ward for the study until after the post screening tests
• subjects who adhere to a special diet (e.g. vegetarians) or lifestyle (incl. working at night and extreme physical activities such as competitive sports and weight lifting) that might interfere with the investigation
• subjects planning elective hospital treatment within one month after last intake of trial medication
• subjects who are known or suspected not to comply with the study directives and/or known or suspected not to be reliable or trustworthy
• subjects who are known or suspected not to be capable of understanding and evaluating the information that is given to them as part of the formal information policy (informed consent), in particular regarding the foreseeable risks and discomfort to which they will be exposed.
• Anticipated problems of successfully placing an indwelling venous catheter at the forearms

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Umm Al-Qura University

OTHER

Sponsor Role: collaborator

University of Cologne

OTHER

Sponsor Role: lead

Responsible Party

Prof. Dr. Uwe Fuhr

Prof. Dr. Uwe Fuhr

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Uwe Fuhr

Role: PRINCIPAL_INVESTIGATOR

Department of Pharmacology,University Hospital Cologne

Locations

Department of Pharmacology I, University Hospital Cologne

Cologne, North Rhine-Westphalia, Germany

Countries

Germany

References

Hsin CH, Stoffel MS, Gazzaz M, Schaeffeler E, Schwab M, Fuhr U, Taubert M. Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Sci Rep. 2020 Jul 27;10(1):12457. doi: 10.1038/s41598-020-69326-y.

Reference Type: DERIVED

PMID: 32719417 (View on PubMed)

Other Identifiers

EtOH_CYP_2013_KPUK

Identifier Type: -

Identifier Source: org_study_id